Artal Group S.A. Gritstone Bio, Inc. Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.62 - $2.35 $1.24 Million - $4.7 Million	2,000,000 Added 194.0%	3,030,952 $1.88 Million
Q1 2024 May 13, 2024	BUY	$1.96 - $2.9 $2.02 Million - $2.99 Million	1,030,952 New	1,030,952 $2.65 Million
Q4 2022 Feb 13, 2023	BUY	$2.17 - $3.92 $2.4 Million - $4.34 Million	1,106,194 Added 147.49%	1,856,194 $6.4 Million
Q4 2021 Feb 11, 2022	BUY	$8.76 - $13.71 $6.57 Million - $10.3 Million	750,000 New	750,000 $9.65 Million
Q4 2019 Feb 13, 2020	SELL	$7.07 - $11.61 $1.77 Million - $2.9 Million	-250,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$8.45 - $12.28 $2.11 Million - $3.07 Million	-250,000 Reduced 50.0%	250,000 $2.16 Million
Q2 2019 Aug 09, 2019	BUY	$9.2 - $15.7 $2.76 Million - $4.71 Million	300,000 Added 150.0%	500,000 $5.57 Million
Q3 2018 Nov 09, 2018	BUY	$14.24 - $14.24 $2.85 Million - $2.85 Million	200,000 New	200,000 $2.85 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.